Conclusions
HOFH
In this study, although inclisiran treatment did not result in a statistically significant reduction in LDL-C level compared with placebo, the sustained reduction in PCSK9 levels demonstrates target engagement with inclisiran even in patients with HoFH. Inclisiran was well-tolerated, and the safety findings are consistent with previously reported studies and the overall safety profile. No new safety signals were identified during the study.